SequelSEC

MiNK Therapeutics, Inc. INKT

Biological Products, (No Diagnostic Substances) · CIK 0001840229 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$12.64M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

MiNK Therapeutics, Inc. (INKT) reported net income of -$12.49M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from MiNK Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

MiNK Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$12.64M-$11.29M-$22.92M-$30.95M-$28.36M-$14.64M
Net income-$12.49M-$10.78M-$22.46M-$27.99M-$30.21M-$16.24M
Research & development$5.76M$6.34M$15.49M$23.12M$13.97M$9.51M
Weighted-average diluted sharesshares 4.27Mshares 3.77Mshares 3.44Mshares 33.67Mshares 26.03MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-2.93$-2.86$-6.54$-0.83$-1.16Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.73M$4.31M$7.43M$7.83M$4.64M$1.29M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

MiNK Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$13.36M$4.58M$3.37M$19.64M$38.89MUnavailable
Total assets$14.24M$5.72M$4.55M$21.47M$40.24M$4.56M
Current assets$13.85M$4.99M$3.60M$20.40M$39.63M$4.10M
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$13.03M$6.96M$11.40M$12.68M$16.47M$14.22M
Total equity incl. NCI-$14.23M-$19.59M-$18.06M-$401.30K$23.78M-$53.87M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.43M$2.73M$3.91M$5.82M$3.00M$3.14M

Cash flow

MiNK Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$5.93M-$9.56M-$15.76M-$18.87M-$12.83M-$8.34M
Capital expendituresUnavailableUnavailable$73.56K$250.05K$248.98K$95.21K
Investing cash flowUnavailableUnavailable-$73.56K-$250.05K-$248.98K-$95.21K
Financing cash flow$14.72M$10.82M-$407.17K-$155.60K$49.26M$11.11M
Net change in cash$8.78M$1.21M-$16.27M-$19.25M$36.20M$2.39M
Stock-based compensation$2.67M$1.81M$3.86M$3.03M$1.74M$87.83K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

MiNK Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailable-$15.84M-$19.12M-$13.08M-$8.43M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.06x0.72x0.32x1.61x2.41x0.29x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INKT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.